HUTCHMED (China) (HCM) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 125.5% versus a loss of 12.0%. Over five years, HCM leads with a -56.3% price change compared with -79.9% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.76 billion vs $2.45 billion), about 1.1 times the size, while HUTCHMED (China) is growing revenue faster (-13.0% vs -28.3%).
HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -70.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | MRVI |
|---|---|---|
| Share price | $14.10 | $7.44 |
| Market cap | $2.45B | $2.76B |
| 1-day change | +3.15% | +3.19% |
| YTD return | +5.78% | +128.92% |
| 1-year return | -11.99% | +125.45% |
| 5-year return | -56.35% | -79.94% |
| P/E ratio (TTM) | 141.00 | — |
| Forward P/E | 54.40 | — |
| EPS (TTM) | $0.10 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $185.74M |
| Revenue growth (YoY) | -12.96% | -28.34% |
| Net income (latest FY) | $456.91M | $-130.77M |
| Gross margin | 38.68% | 18.30% |
| Operating margin | -7.14% | -115.89% |
| Net margin | 83.30% | -70.41% |
| 52-week high | $16.33 | $9.42 |
| 52-week low | $9.77 | $2.55 |
| Distance from 52-week high | -13.66% | -21.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +56.10% | +5.24% |
| Average volume | 68.02K | 3.34M |
| Shares outstanding | 173.81M | 148.99M |
| Employees | 1,790 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed HCM by 137.4 percentage points over the past year.
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -70.4 cents for Maravai LifeSciences.
- HUTCHMED (China) grew revenue faster in its latest fiscal year (-12.96% vs -28.34%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
HCM vs MRVI FAQ
Which is bigger, HUTCHMED (China) or Maravai LifeSciences?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.76B compared with $2.45B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or MRVI?
MRVI returned +125.45% over the past 12 months, compared with -11.99% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.